Merck and Moderna say their personalised cancer therapy passed a Phase 3 trial. A machine learning model picks up to 34 targets from a patient's own tumour, and those go into mRNA so the immune syste…
Source: Merck and Moderna: Phase 3 INTerpath-001 met RFS and DMFS endpoints